HCM
HZNP

Hollencrest Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Hollencrest Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-95
Closed -$11K – 1141
2023
Q3 		$11K Hold
95
– – ﹤0.01% 714
2023
Q2 		$9.77K Hold
95
– – ﹤0.01% 759
2023
Q1 		$10.4K Buy
+95
New +$10.5K ﹤0.01% 739

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Hollencrest Capital Management's HZNP Position: Q4 2023 in Review

Hollencrest Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 95 shares — an estimated $11K sold.

Hollencrest Capital Management first reported a position in HZNP in Q1 2023 and held it in 3 quarters. The position peaked at $11K in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Hollencrest Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Hollencrest Capital Management sold 95 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $11K.
  • Hollencrest Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023 and held it in 3 quarters.
  • Hollencrest Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $11K in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Hollencrest Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.